Immunocal® limits gliosis in mouse models of repetitive mild-moderate traumatic brain injury.

"Declaration of Competing Interest: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors have received funding from Immunotec Inc. (Quebec, Canada) to support research on the therapeutic effects of Immunocal® in pre-clinical mouse models of TBI. DAL is currently a member of the Scientific Advisory Board for Immunotec Inc."

"Funding: This study was supported in large part by funding from Immunotec Inc. (Quebec, Canada), which is the manufacturer of Immunocal®. The University of Colorado Animal Imaging Shared Resources are supported by the University of Colorado Cancer Center (NCI P30 CA046934) and the Colorado Clinical and Translational Sciences Institute (NIH/NCATS UL1 TR001082). CRediT authorship contribution statement: Lilia A. Koza: Investigation, Resources, Validation, Formal analysis, Writing – original draft, Writing – review & editing, Visualization, Supervision, Project administration. Claudia Pena: Investigation, Resources, Validation. Madison Russell: Investigation, Validation. Alec C. Smith: Investigation, Validation. Jacob Molnar: Investigation, Validation. Maeve Devine: Investigation, Validation. Natalie J. Serkova: Methodology, Investigation, Resources, Validation, Supervision, Writing – review & editing. Daniel A. Linseman: Conceptualization, Methodology, Investigation, Resources, Writing – review & editing, Supervision, Project administration, Funding acquisition."